-
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Lameris, R., Ruben, J. M., Iglesias-Guimarais, V., de Jong, M., Veth, M., van de Bovenkamp, F. S., de Weerdt, I., Kater, A. P., Zweegman, S., Horbach, S., Riedl, T., Winograd, B., Roovers, R. C., Adang, A. E. P., de Gruijl, T. D., Parren, P. W. H. I. & van der Vliet, H. J., 21 Mar 2023, In: Cell Reports Medicine. 4, 3, p. 100961 100961.Research output: Contribution to journal › Article › Academic › peer-review
-
A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia
de Weerdt, I., Lameris, R., Ruben, J. M., de Boer, R., Kloosterman, J., King, L. A., Levin, M-D., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P. & van der Vliet, H. J., 1 Mar 2021, In: Clinical Cancer Research. 27, 6, p. 1744-1755 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
A bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies
de Weerdt, I., Lameris, R., Scheffer, G. L., Vree, J., de Boer, R., Stam, A. G., van de Ven, R., Levin, M-D., Pals, S. T., Roovers, R. C., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P. & van der Vliet, H. J., 1 Jan 2021, In: Cancer immunology research. 9, 1, p. 50-61 12 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
